Similar to STAT3-HIES, patients with DIDS frequently have treatment-resistant AD, and the efficacy of dupilumab in this population has been described in limited case reports demonstrating efficacy of dupilumab treatment (61, 62, 69). This evidence concerns the gene STAT3 and Alzheimer disease.